| abstract |
The present invention provides a compound of the formula (I) or (II), wherein R1~ is H, alkyl, alkenyl or aryl, R2~ is H, alkyl, alkenyl or aryl, R3~ is H, alkyl, alkenyl or aryl, R4~ and R4~-R8~ are independently R10~, C(O)R10~ or SO~2R10~, wherein R10~ is H, alkyl, alkenyl or aryl, and R9~ is R9a~, C(O)R9a~ or SO~2R9a~, wherein R9a~ is H, alkyl, alkenyl or aryl. R9a~ can be unsubstituted or substituted with one or more oxo(=O), OR9b~, OC(O)R9b~, OSO~2R9b~, NHR9b~, NHC(O)R9b~ and NHSO~2R9b~ groups. R9b~ is H, alkyl, alkenyl, or aryl. R9b~ can be unsubstituted or substituted with one or more groups such as oxo(=O), OR9c~, CO~2R9c~, CO~2R9c~ and OC(O)R9c~. R9c~ is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer. |